Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Galiximab

Generic Name: Galiximab

Drug Type: Biotech

CAS Number: 357613-77-5

Unique Ingredient Identifier: S9OX9692ZB

Overview

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Background

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.

Associated Conditions

No associated conditions information available.

Clinical Trials

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Phase 1

Terminated

Posted: 2008/04/02

Sponsor:Biogen

ID:NCT00651443

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3

Terminated

Posted: 2006/10/05

Sponsor:Biogen

ID:NCT00384150

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Phase 3

Terminated

Posted: 2006/08/15

Sponsor:Biogen

ID:NCT00363636

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma

4 years ago

CAR-T cell therapy has emerged as a promising treatment for Non-Hodgkin Lymphoma (NHL), particularly for patients with chemotherapy-resistant forms of the disease. This article reviews the structure, molecular mechanisms, clinical trial results, and challenges of CAR-T cell-based therapies, focusing on their application in NHL.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy